J. M. Ladowski1, G. Martens1, L. Reyes1, Z. Wang1, M. Tector1, A. J. Tector1 1University Of Alabama at Birmingham,Birmingham, Alabama, USA
Introduction: Xenotransplantation, using genetically-modified swine, represents a solution to the organ shortage and is rapidly approaching clinical trials. Avoiding recipients with donor-specific major histocompatibility complex (MHC) antibodies greatly extends graft life. There exist many tools to screen allotransplant recipients for the presence, specificity, and consequence of antibodies but few reagents to screen potential xenotransplant recipients. Therefore, the prevalence, specificity, and immunogenic potential of anti-swine MHC class II antibodies remains unknown.
Methods: Broadly positive swine MHC class II cells were generated by transfection with a human class II transactivator transgene and single antigen cells were made by expression of swine class II heavy chains. Serum from 237 waitlisted patients were screened using a flow cytometry crossmatch. Positive samples were further assessed for complement activation with a complement dependent cytotoxicity assay.
Results: The screening flow cytometry crossmatch revealed 30/237 (12.6%) samples with potential anti-pig MHC class II antibodies. The 30 sera were tested on single allele swine cells and showed binding predominately to swine DQ alleles. Antibodies were able to activate complement and showed an increased killing of MHC-DQ relative to MHC-DR positive cells.
Conclusion: Reagents to screen potential xenotransplant recipients for the presence, specificity, and consequence of antibodies were produced. The methods detected many patients with haplotype specific anti-swine MHC class II antibodies capable of activating complement, especially against swine-DQ alleles. Lessons from allotransplantation show importance of screening and avoiding patients with these donor-specific antibodies.